The partnership will see Pharmadule Morimatsu deliver modular facilities for CDMO WuXi Biologics at its Singapore plant.
Pharmadule, a company focused on delivering pharmaceutical manufacturing facilities, will initially begin the partnership with the integrated modular plant of two production facilities at contract development manufacturing organization (CDMO) WuXi Biologics’ Singapore center.
Pharmadule will be responsible for the design, production, installation, commissioning, and the validation of the modular plants. Additionally, the company will build, assemble, and carry out Facility Acceptance Testing (FAT) at its off-site workshop.
DepositPhotos/olinchuk
“Compared with conventional construction, modular facilities allow the quality, schedule, cost, and risk associated with the project to be well managed and controlled. It is part of the strategy to enable a successful and efficient establishment of the Singapore CRDMO Center with comprehensive capabilities,” Chris Chen, CEO of WuXi Biologics, told BioProcess Insider.
The first modular facility is expected to be operational in 2025 and when asked how many facilities are planned to be constructed, Chen told us “the entire site would have a mix of conventionally constructed and modular facilities.”
No financial details have been disclosed but according to both parties, this collaboration acts as a strategic move to engage with more customers globally. Moreover, WuXi Biologics and Pharmadule said they would continue to seek further partnership opportunities.
“WuXi Biologics is an important partner of our company, we are very delighted to cooperate with them once again. In this cooperation, Pharmadule Morimatsu will utilize a new generation of modular fabrication methods to assist WuXi Biologics in expanding production capacity, accelerating the empowerment of global pharmaceutical companies, reducing R&D costs, and benefiting patients worldwide,” Weihua Tang, CEO of Morimatsu LifeSciences, said.
You May Also Like
